JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
See More: http://goo.gl/tW6DQL
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
9.3.3 Takeda Pharmaceuticals 216<br />
9.3.4 Warner Chilcott 218<br />
9.3.5 Salix Pharmaceuticals/Santarus 220<br />
9.3.6 Shire Pharmaceuticals 222<br />
9.3.7 Ferring Pharmaceuticals 224<br />
9.3.8 Pfizer 225<br />
9.3.9 InDeX Pharmaceuticals 227<br />
10 <strong>Market</strong> Outlook 230<br />
10.1 <strong>Global</strong> <strong>Market</strong>s 230<br />
10.1.1 <strong>Forecast</strong> 230<br />
10.1.2 Drivers <strong>and</strong> Barriers - <strong>Global</strong> Issues 235<br />
10.2 United States 239<br />
10.2.1 <strong>Forecast</strong> 239<br />
10.2.2 Key Events 243<br />
10.2.3 Drivers <strong>and</strong> Barriers 243<br />
10.3 France 246<br />
10.3.1 <strong>Forecast</strong> 246<br />
10.3.2 Key Events 250<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language